Navigation Links
New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease

NEW YORK, May 4, 2012 /PRNewswire/ -- The Lupus Research Institute (LRI) applauds our colleagues at the American College of Rheumatology (ACR) for issuing new guidelines to help healthcare professionals screen, diagnose and treat lupus nephritis, a type of kidney disease associated with lupus. Available on the ACR website, the new guidelines are just published in the April 2012 issue of Arthritis Care & Research.

An estimated one third of people with lupus are affected by lupus nephritis – a serious consequence of lupus in which the immune system attacks the kidneys. While nine out of 10 people with lupus are women, men with the disease are more prone to lupus nephritis.

The kidneys keep the balance of fluids in the body at the right levels, taking out waste and extra water from the blood and sending these out of the body through urine. The kidneys also help to control hormone levels and the amount of pressure in the blood vessels. If lupus attacks the kidneys, these functions are impeded and harmful toxins can start to build up in the blood, causing serious damage.

Lupus Nephritis Guidelines Codify Diagnosis and Treatment

The 2012 lupus nephritis guidelines were formulated through a thorough review by three panels of researchers of the medical literature from 1966 through 2010 for all evidence pertaining to "lupus kidney disease".

"It has been over a decade since guidelines for treatment of lupus nephritis were published, and much has changed since with new immunosuppressive and antihypertensive drugs as well as new therapeutics that work directly to reduce loss of kidney function," commented Betty Diamond, MD, Chief, Autoimmune Disease Center, Feinstein Institute for Medical Research, North Shore-LIJ Health System and Advisor-at-Large of the LRI Scientific Advisory Board. "It is very important that physicians have guidelines to help them make therapeutic decisions and to ensure that certain helpful strategies are not overlooked. However, the ultimate therapeutic plan will still be determined case by case by the patient and their physician."

The Lupus Research Institute is also strongly committed to improving early diagnosis and treatment of lupus nephritis by funding innovative research on the mechanisms of kidney damage and novel ways to monitor lupus nephritis; read more on LRI grants completed or in progress focusing on lupus nephritis. Most recently, discoveries from LRI-funded studies include biomarkers to diagnose and assess lupus nephritis while avoiding the need for invasive surgical biopsy. A new LRI study by Dr. Janusz Kabarowski, University of Alabama, Birmingham investigates the possibility of harnessing the anti-inflammatory properties of high-density lipoproteins (good cholesterol HDL) to protect the heart and blood vessels, and stem the immune system's attack on other vital organs including the kidneys.

"Because so many of our patients suffer from kidney disease, LRI scientific studies in the field of lupus nephritis are robust," noted LRI President Margaret Dowd. "We will support the ACR's efforts to educate patients and professionals on the need for early screening for lupus kidney disease when the condition is most treatable."

About the Lupus Research Institute

Now the world's leading private supporter of innovative research in lupus, the Lupus Research Institute is also supported by a Coalition of patient advocacy organizations across the country, primarily in the nation's urban centers. For more information, visit

SOURCE Lupus Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Published in Molecular Therapy Shows that Immune Response to FANG™ Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
2. Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys
3. CAS and Taylor & Francis Collaborate to Improve Scientists Access to Published Research
4. Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism
5. Study Published in Neuro-Oncology Journal Shows Brain Tumor Eradication and Prolonged Survival in Mice Treated With Toca 511 and 5-FC
6. Independent Data Published on BioLife Solutions HypoThermosol® and CryoStor®
7. BioElectronics Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
8. Results From Pilot Trial of PLCs RenalGuard® Published in International Journal of Cardiology
9. SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
10. Data Published in EuroIntervention Indicate that OrbusNeichs Genous™ Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy
11. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):